Novavax COVID-19 vaccine 89% effective in late-stage trials; less efficacy seen against South African variant

January 29, 2021

Novavax COVID-19 vaccine 89% effective in late-stage trials; less efficacy seen against South African variant
By Madeline Farber

The Maryland-based biotech firm Novavax on Thursday announced the results of its late-stage clinical trial in Britain, finding that its two-dose jab was around 89% effective in preventing COVID-19 illness.